Ph+ ALL: drawing strength from a benign past

Slides:



Advertisements
Similar presentations
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Advertisements

Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells by Catarina M. Henriques, José Rino, Robert J.
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Uncontrolled Wnt signaling causes leukemia
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
MBL: mostly benign lymphocytes, but…
by Dai Chida, Osamu Miura, Akihiko Yoshimura, and Atsushi Miyajima
Fledgling prognostic markers in CLL
Positioning NK-κB in multiple myeloma
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
When monocyte life hangs by a thread
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Juvenile Myelomonocytic Leukemia
Tax fingerprint in adult T-cell leukemia
BRAF inhibitor: targeted therapy in hairy cell leukemia
Rethinking bioactivity of FLT3 inhibitors
Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
V617F “JAKs” up myeloproliferative signal
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Targeting kinases in CML CLL
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML by Srila Gopal, Qing Lu, Joshua.
Interleukin-21 is a growth and survival factor for human myeloma cells
Target recognition–induced NK-cell responses
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Walter Zumkeller, and Stefan Burdach
Lymphoma spread? Target CD47-SIRPα!
Figure 1 Therapeutic targeting of the B-cell receptor (BCR)
Anergy: the CLL cell limbo
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.
by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty
Janus Kinase Deregulation in Leukemia and Lymphoma
Volume 20, Issue 1, Pages 3-5 (July 2011)
Detection rate for EGFR mutations in cfDNA.
Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL by Kathryn G. Roberts, Yung-Li Yang, Debbie.
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Volume 123, Issue 6, Pages (December 2002)
BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.
by Eric J. Vick, Kruti Patel, Philippe Prouet, and Mike G. Martin
Oncogenic ALK signaling.
Kinase signaling and targeted therapy for primary myelofibrosis
Platelet ATP secretion in response to agonist stimulation.
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
HoxA9 directly regulates cell cycle control genes.
by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Sickle cells and sickle trait in thrombosis
Schematic model of the mechanism of Tak1 protection of HSPC survival.
ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity
How I treat thrombocytopenia in pregnancy
Fig. 1 Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia. Effects of protein phosphatase.
Co-opted integrin signaling in ErbB2-induced mammary tumor progression
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Anti-CD20-IL-21 fusokine: the tail wags the dog
Protein expression profile in a dasatinib-resistant cell line.
Attacking Cancer at Its Root
Influence of the tumor microenvironment on FL
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate. Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate.
A schematic representation of NOTCH signaling through DAB1–ABL–TRIO–RHO that stimulates colorectal cancer invasion and metastasis. A schematic representation.
Patient Tregs express normal levels of suppression.
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.
BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.
Although equivalent experimental systems have been employed in a variety of assessments to determine BCR-ABL1 kinase domain mutation sensitivity on the.
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
Cold agglutinin disease
Presentation transcript:

Ph+ ALL: drawing strength from a benign past by Markus Müschen Blood Volume 125(19):2879-2880 May 7, 2015 ©2015 by American Society of Hematology

Survival and proliferation of normal mouse pre-B cells are promoted by IL-7R signaling and activation of JAK and STAT5 (A). Survival and proliferation of normal mouse pre-B cells are promoted by IL-7R signaling and activation of JAK and STAT5 (A). After malignant transformation of pre-B cells by BCR-ABL1 (Ph+ ALL), IL-7R signaling becomes redundant in ALL cells (B). Mallampati et al show that TKIs of BCR-ABL1 (eg, dasatinib) may effectively block BCR-ABL1 tyrosine kinase activity but concurrently induce IL-7 secretion in MSCs. TKI-induced IL-7 secretion by MSCs can, hence, restore IL-7R–mediated survival and proliferation signaling in Ph+ ALL cells (C). Although reinstatement of IL-7R and JAK signaling as in normal pre-B cells induces drug resistance, dual targeting of both BCR-ABL1 (eg, dasatinib) and JAK (eg, ruxolitinib) activity can prevent IL-7R-JAK–dependent survival signaling and short-circuit drug resistance (D). Markus Müschen Blood 2015;125:2879-2880 ©2015 by American Society of Hematology